Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T ...

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in ...

Highlights in acute lymphoblastic leukemia (ALL), presented at the American ... He then turns to CAR T-cell immunotherapy in the frontline setting for adults 55 or older, a population for whom ...

One such type is Acute Lymphoblastic Leukemia (ALL), which is characterised by the uncontrolled proliferation of immature white blood cells known as lymphoblasts. This condition can disrupt normal ...

Promising Cell Therapy Offers Hope for Relapsed or Refractory T-Cell Leukaemia Oct. 7 ... in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

A phase 2 study explored a novel bicistronic CD19/CD22-directed CAR-T cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL). Most children in the study achieved remission, meaning ...